Andrew Tsai
Stock Analyst at Morgan Stanley
(0.37)
# 3,974
Out of 4,784 analysts
18
Total ratings
25%
Success rate
-22.59%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $20.59 | +31.13% | 2 | Mar 19, 2025 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $29 | $7.59 | +282.08% | 1 | Dec 18, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $70.41 | +134.34% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.30 | +4,281.53% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $10.05 | +248.26% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.27 | +1,353.74% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.59 | +479.15% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.57 | +425.85% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.31 | +883.61% | 2 | Jun 23, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $20 | $1.91 | +947.12% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $70 | $131.81 | -46.89% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.47 | +1,736.73% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $34.26 | -32.87% | 1 | Jun 1, 2020 |
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $20.59
Upside: +31.13%
Rocket Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $29
Current: $7.59
Upside: +282.08%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $70.41
Upside: +134.34%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.30
Upside: +4,281.53%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $10.05
Upside: +248.26%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.27
Upside: +1,353.74%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.59
Upside: +479.15%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.57
Upside: +425.85%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.31
Upside: +883.61%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $1.91
Upside: +947.12%
Sep 20, 2021
Maintains: Buy
Price Target: $55 → $70
Current: $131.81
Upside: -46.89%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.47
Upside: +1,736.73%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $34.26
Upside: -32.87%